Examples of 'progression-free' in a sentence
Meaning of "progression-free"
progression-free is used to describe a medical state where a disease such as cancer is not advancing or progressing
How to use "progression-free" in a sentence
Basic
Advanced
progression-free
Progression-free survival was the primary endpoint.
The main measure of effectiveness was progression-free survival.
Median progression-free survival by independent assessment.
The treatment goal at present is progression-free survival.
Progression-free survival was better with sunitinib.
Statistically significant improvements in progression-free survival were also observed.
Median progression-free survival not reached yet.
However a statistically significant effect was seen on progression-free survival.
Progression-free survival was an exploratory endpoint.
A statistically significant improvement in progression-free survival was also observed.
Progression-free survival corresponds to absence of local or distance failure.
Approval will be based on a primary endpoint of progression-free survival.
Progression-free survival by time from last platinum therapy to recurrence.
We saw a more than doubling in median progression-free survival.
Progression-free survival assessed by biochemistry, radiology and immunology tests.
See also
Although there was an improvement in progression-free survival, this was considered to be small.
Progression-free survival rates are an indication of how effective a particular treatment is.
More than half remained progression-free a full year out.
Median progression-free and overall survival have not been reached.
The primary efficacy endpoint of the study is progression-free survival.
The median progression-free survival has not yet been reached.
It is remarkably well tolerated and results in longer progression-free survival.
Secondary endpoints included progression-free survival and objective response rate.
In an embodiment the administration of the combination increases progression-free survival.
Their possibility of improved progression-free survival and overall survival.
But do we know anything about the duration of response or progression-free survival?
These indexes include progression-free survival and observed survival rates.
Another well accepted marker for efficacy is progression-free survival.
The primary endpoint was progression-free survival ; overall survival was a secondary endpoint.
Primary outcomes were overall survival and radiographic progression-free survival.
Progression-free survival was also improved with pirfenidone compared with placebo.
To evaluate the duration of response, progression-free survival and overall survival.
These expanded indications are approved under accelerated approval based on progression-free survival.
The co-primary study endpoints were progression-free survival and overall survival.
The combination did not show a statistically significant improvement in progression-free survival.
It is an active agent whose effect on progression-free survival has now been established.
When used following chemotherapy and radiation, it was found to improve progression-free survival.
The primary end point was progression-free survival as assessed by an independent review committee.
The secondary endpoints are overall survival and progression-free survival.
Information on progression-free survival and health-related quality of life were not available.
Detecting an overall survival benefit that is derived from progression-free survival.
The primary endpoint was focused on progression-free survival, and it was a very positive study.
Co-primary efficacy endpoints were overall survival and radiographic progression-free survival rPFS.
The patient may have had a progression-free interval of less than six months.
The primary efficacy parameter of the trial was the duration of progression-free survival.
Secondary outcome measures included progression-free survival and objective response rate.
The primary endpoints of the trial were objective response rate and progression-free survival.
The median progression-free survival among all the patients was about a year.
The secondary objectives included progression-free survival and drug safety.
In some embodiments of the methods of the invention, the administrations increase progression-free survival.
